The Courts and Post-Dobbs Access to Reproductive Care: Implications of the Mifepristone and Medical Abortion Lawsuits (On-Demand Webinar)
Overview: Post-Dobbs, medication abortion has been a prime topic of litigation across the country. The Food and Drug Administration (FDA) has faced competing decisions involving mifepristone, a medication used in half the abortions in this country. In Texas, a group of physicians argue that the FDA should not have approved the drug in 2000 or loosened restrictions to allow mail-ordered distribution. In Washington, states claim that the FDA must lift the remaining restrictions on mifepristone. Other suits argue that state restrictions on distribution of mifepristone are preempted by the FDA’s regulations. This litigation has significant implications for the pharmaceutical industry, medical practice, and abortion access across the country.
Elizabeth W Sepper, Professor, University of Texas School of Law
Zoraima Pelaez, Equal Justice Fellow, ACLU
Sheela Ranganathan, Associate, Sheppard Mullin
CLE: AHLA’s live distance learning webinars are pre-approved for CLE credit in the following states: AL, AR, CA, IL, IN, GA, KS, ME, MI, MS, NC, NE, NJ, OH, OK, PA, RI, SC, TN, TX, UT, VA, VT, WI, and WV. Please refer to the Distance Learning CLE State Chart on our Continuing Education page to review the reporting procedure in these state
CPE: AHLA is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be addressed to the National Registry of CPE Sponsors, 150 Fourth Avenue North, Nashville, TN 37219-2417. Website: www.nasba.org. For further information, please visit our Continuing Education Page.
AHLA is seeking CPE credits for live and on demand webinars. The maximum number of credits available is 1.80.